DVAX logo

Dynavax Technologies Corporation

DVAX

DVAX: Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

more

Show DVAX Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of DVAX by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by DVAX's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $80,000 Jul 14, 2023 Issue: None
  • $120,000 Apr 20, 2023 Issue: Health Issues
  • $90,000 Jan 20, 2023 Issue: None
  • $90,000 Oct 19, 2022 Issue: None
  • $90,000 Jul 20, 2022 Issue: None
  • $120,000 Apr 20, 2022 Issue: Health Issues
  • $50,000 Jan 20, 2022 Issue: HEALTH ISSUES
  • $75,000 Oct 20, 2021 Issue: Pharmacy
  • $75,000 Jul 15, 2021 Issue: Pharmacy
  • $75,000 Apr 15, 2021 Issue: Pharmacy
  • $75,000 Jan 18, 2021 Issue: Pharmacy
  • $75,000 Oct 06, 2020 Issue: Pharmacy
  • $75,000 Oct 06, 2020 Issue: Pharmacy
  • $65,000 Oct 06, 2020 Issue: Pharmacy
  • $45,000 Jan 14, 2020 Issue: Pharmacy
  • $45,000 Oct 07, 2019 Issue: Pharmacy
  • $45,000 Jul 03, 2019 Issue: Pharmacy
  • $45,000 Apr 10, 2019 Issue: Pharmacy
  • $45,000 Jan 18, 2019 Issue: Pharmacy
  • $45,000 Oct 18, 2018 Issue: Pharmacy
  • $45,000 Jul 26, 2018 Issue: Pharmacy
  • $45,000 Apr 30, 2018 Issue: Pharmacy
  • $20,000 Feb 12, 2018 Issue: Pharmacy
  • $45,000 Oct 23, 2017 Issue: Pharmacy
  • $45,000 Jul 20, 2017 Issue: Pharmacy
  • $25,000 Apr 20, 2017 Issue: Pharmacy
  • $20,000 Jan 24, 2017 Issue: Pharmacy
  • $10,000 Oct 19, 2016 Issue: Pharmacy
  • $10,000 Jul 19, 2016 Issue: Pharmacy
  • $10,000 Apr 18, 2016 Issue: Pharmacy
  • $20,000 Oct 21, 2015 Issue: Pharmacy
  • $20,000 Jul 16, 2015 Issue: Pharmacy
  • $20,000 Apr 20, 2015 Issue: Pharmacy
  • $20,000 Jan 14, 2015 Issue: Pharmacy
  • $20,000 Oct 14, 2014 Issue: Pharmacy
  • $20,000 Jul 14, 2014 Issue: Pharmacy
  • $20,000 Jun 02, 2014 Issue: Pharmacy
  • $60,000 Oct 08, 2013 Issue: Pharmacy
  • $20,000 Aug 06, 2013 Issue: Pharmacy
  • $20,000 Aug 06, 2013 Issue: Pharmacy
U.S. Patents

New patents grants

  • Patent Title: Toll-like receptor antagonist compounds and methods of use Jun. 28, 2022
  • Patent Title: Alkyl chain modified imidazoquinoline tlr7/8 agonist compounds and uses thereof Sep. 21, 2021
  • Patent Title: Cleavable conjugates of tlr7/8 agonist compounds, methods for preparation, and uses thereof Jul. 28, 2020
  • Patent Title: Branched chimeric compounds, and methods of use thereof Feb. 04, 2020
  • Patent Title: Administration of polynucleotide toll-like receptor 9 agonists for treating cancer Aug. 06, 2019
  • Patent Title: Linear chimeric compounds and methods of use thereof Jul. 16, 2019
  • Patent Title: Methods and compositions for eliciting an immune response against hepatitis b virus Jun. 11, 2019
  • Patent Title: Immunostimulatory sequence oligonucleotides and methods of using the same Feb. 05, 2019
  • Patent Title: Intrapulmonary administration of polynucleotide toll-like receptor 9 agonists for treating cancer of the lung Oct. 30, 2018
  • Patent Title: Intrapulmonary administration of polynucleotide toll-like receptor 9 agonists for treating cancer of the lung Jun. 12, 2018
  • Patent Title: Branched and linear chimeric compounds, polynucleotides, uses and methods for preparation thereof Apr. 24, 2018
  • Patent Title: Methods and compositions for eliciting an immune response against hepatitis b virus Feb. 06, 2018
  • Patent Title: Human toll-like receptor inhibitors and methods of use thereof Jan. 16, 2018
  • Patent Title: Methods and compositions for inhibition of immune responses and autoimmunity Oct. 25, 2016
  • Patent Title: Methods and compositions for eliciting an immune response against hepatitis b virus Sep. 27, 2016
  • Patent Title: Immunostimulatory sequence oligonucleotides and methods of using the same Aug. 23, 2016
  • Patent Title: Methods of treatment using tlr7 and/or tlr9 inhibitors May. 24, 2016
  • Patent Title: Long term disease modification using immunostimulatory oligonucleotides May. 10, 2016
  • Patent Title: Human toll-like receptor inhibitors and methods of use thereof Jan. 05, 2016
  • Patent Title: Transgenic mice expressing human toll-like receptor 8 Jun. 23, 2015
  • Patent Title: Chimeric immunomodulatory compounds and methods of using the same-iv May. 12, 2015
  • Patent Title: Methods and compositions for inhibition of immune responses and autoimmunity Feb. 24, 2015
  • Patent Title: Methods of treatment using tlr7 and/or tlr9 inhibitors Jan. 27, 2015
  • Patent Title: Immunostimulatory sequence oligonucleotides and methods of using the same Oct. 28, 2014
  • Patent Title: Compositions comprising structurally stable conjugate molecules Oct. 14, 2014
  • Patent Title: Long term disease modification using immunostimulatory oligonucleotides Aug. 26, 2014
  • Patent Title: Methods and compositions for inhibition of innate immune responses and autoimmunity Jun. 24, 2014
  • Patent Title: Biodegradable immunomodulatory formulations and methods for use thereof Mar. 11, 2014
  • Patent Title: Chimeric immunomodulatory compounds and methods of using the same-iv Dec. 03, 2013
  • Patent Title: Immunomodulatory compositions, formulations, and methods for use thereof Nov. 19, 2013
  • Patent Title: Immunomodulatory polynucleotides and methods of using the same Feb. 12, 2013
  • Patent Title: Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein Dec. 18, 2012
  • Patent Title: Long term disease modification using immunostimulatory oligonucleotides Aug. 28, 2012
  • Patent Title: Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide sequences Jul. 24, 2012
  • Patent Title: Chimeric immunomodulatory compounds and methods of using the same-ii Jul. 17, 2012
  • Patent Title: Immunostimulatory sequence oligonucleotides and methods of using the same Apr. 17, 2012
  • Patent Title: Biodegradable immunomodulatory formulations and methods for use thereof Feb. 28, 2012
  • Patent Title: Chimeric immunomodulatory compounds and methods of using the same—iv Feb. 14, 2012
  • Patent Title: Chimeric immunomodulatory compounds and methods of using the same Aug. 23, 2011
  • Patent Title: Immunomodulatory compositions, methods of making, and methods of use thereof Feb. 08, 2011
  • Patent Title: Chimeric immunomodulatory compounds and methods of using the same—iii Aug. 31, 2010
  • Patent Title: Immunostimulatory sequence oligonucleotides and methods of using the same Jun. 29, 2010
  • Patent Title: Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences Jun. 01, 2010
  • Patent Title: Compositions comprising structurally stable conjugate molecules May. 18, 2010
Government Contracts

Federal grants, loans, and purchases

WallStreetBets

Number of mentions of DVAX in WallStreetBets Daily Discussion

DVAX News

Recent insights relating to DVAX

CNBC Recommendations

Recent picks made for DVAX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in DVAX

Corporate Flights

Flights by private jets registered to DVAX